J&J invests $500m into global HIV and TB treatment

Johnson & Johnson (J&J) has committed $500 million to research and development programmes over the next four years in a bid to eliminate HIV and tuberculosis (TB) across the world by 2030.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk

More on this story

Big Pharma

Global Drug Facility adds new TB drug to its catalogue

31 October 2019 The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.

Big Pharma

Federal Circuit rules against J&J in Zytiga dispute

16 May 2019 The US Court of Appeals for the Federal Circuit delivered a blow to Johnson & Johnson on Tuesday, May 14, by confirming the invalidation of a patent covering blockbuster prostate cancer drug Zytiga.

More on this story

Big Pharma

Global Drug Facility adds new TB drug to its catalogue

31 October 2019 The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.

Big Pharma

Federal Circuit rules against J&J in Zytiga dispute

More on this story

Big Pharma

Global Drug Facility adds new TB drug to its catalogue

31 October 2019 The Global Drug Facility, which provides tuberculosis treatments to those in need in 150 countries, has listed a new drug to its product catalogue.

Big Pharma

Federal Circuit rules against J&J in Zytiga dispute